Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in corticosteroid-dependent pulmonary sarcoidosis
NCT03793439Phase 1Completed
- Sponsor
- Oregon Health & Science University
- Start
- May 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tofacitinib oral solution in pulmonary sarcoidosis, sponsored by Oregon Health & Science University. Primary endpoint: Number of Participants With 50% Reduction in Corticosteroid Requirement at 16 weeks. Started May 2019; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
pulmonary sarcoidosis
Beyond the preview
Go deeper on NCT03793439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03793439.